Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706119 | 1.00 | NPSR1 (0.35) | NPSR1USP2TDP1GABRR1GABRR2 | |
| SCHEMBL2707257 | 1.00 | NPSR1 (0.35) | NPSR1USP2TDP1GABRR1GABRR2 | |
| SCHEMBL2426403 | 0.87 | USP2 (0.35) | NPSR1USP2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL2706125 | 0.86 | HPGD (0.37) | TDP1PTGS1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL2706126 | 0.86 | HPGD (0.37) | TDP1PTGS1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL4458952 | 0.84 | ALDH1A1 (0.43) | NPSR1USP2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL4458950 | 0.84 | ALDH1A1 (0.43) | NPSR1USP2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL2706959 | 0.83 | — | — | |
| SCHEMBL2706956 | 0.83 | — | — | |
| SCHEMBL2707781 | 0.82 | TTR (0.40) | NPSR1USP2LMNAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139841-B1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2012-05-02 | — | — | EP | claimed |
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | US | claimed |
| EP-2139841-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | claimed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | claimed |
| JP-60109537-A | — | — | None | — | — | JP | disclosed |
| EP-4138574-A1 | COMPOSITIONS | Givaudan SA (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214008-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214008-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20200345049-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2020-11-05 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9451784-B2 | Off-note blocking sensory organic compounds | GIVAUDAN S.A. (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20100129833-A1 | Methods to Identify Modulators | GIVAUDAN SA (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2139841-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2137322-A1 | METHODS TO IDENTIFY MODULATORS | Givaudan SA (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008119195-A1 | METHODS TO IDENTIFY MODULATORS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119195-A1 | METHODS TO IDENTIFY MODULATORS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119196-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-09 | — | — | WO | disclosed |
| JP-S60109537-A | CYCLOPENTENE DERIVATIVE | T HASEGAWA CO LTD | 1985-06-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284944-A1 | OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS | SORD, OTC, ASPH | NPSR1 1185/4885USP2 4815/4885TDP1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.